Phage therapy program
MicrobiotiX Co Ltd
| Status | Research/development |
|---|---|
| Type | Company |
| Location | Seoul; South Korea |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Developer and sponsor of MP101; corporate contact mx@microbiotix.net / bd@microbiotix.net. Patient enrollment belongs to NCT07492771 at Severance Hospital; no expanded-access company route verified. |
|---|---|
| Areas of work | MP101 bacteriophage treatment for P. aeruginosa pneumonia. Official August 2026 release reports completion of the sentinel cohort in first-in-human phase1 trial. |
| International access | Not stated in checked sources; do not infer eligibility from international collaborations. |
What to confirm
- Development-only describes lack of a general company treatment-access service, not absence of human trials.
Related studies(1)
MP101-1001
Recruiting
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- MicrobiotiX company introduction
- MicrobiotiX completes MP101 sentinel cohort
- ClinicalTrials.gov NCT07492771
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | kr-microbiotix |
|---|